Company: GNMSF
Filing Date: 2025-09-29
Form Type: SC TO-C
Source: 0000947871-25-000868
Chunk: 1

Company: GENMAB A/S
Filing Date: 2025-09-29
Form: SC TO-C
Chunk 1
---
 under cover
of this Tender Offer Statement on Schedule TO are being filed by Genmab A/S, a public limited liability company incorporated in Denmark
(“Genmab”), pursuant to General Instruction D to Schedule TO related to a planned cash tender offer for all
of the issued and outstanding common shares, nominal value €0.09 per share of Merus N.V., a public limited liability company (naamloze vennootschap) organized under the Laws of The Netherlands (the “Company”) pursuant to the Transaction Agreement,
dated as of September 29, 2025, by and among Genmab, Genmab Holding II B.V., a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) organized under the Laws of the Netherlands and a wholly-owned subsidiary of Genmab (“Purchaser”),
and the Company.

Additional Information

The tender offer for the
common shares of the Company (“”) referenced in this announcement has not yet commenced. This
announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell Common
Shares or any other securities, nor is it a substitute for the tender offer materials that Genmab and Purchaser will file or cause
to be filed with the Securities and Exchange Commission (the “”) upon the commencement of the tender offer.
This communication may be deemed to be solicitation material in respect of the EGM Proposals (defined below). At the time the tender
offer is commenced, Genmab and Purchaser will file or cause to be filed with the SEC a tender offer statement on Schedule TO (the
“”), and the Company will file with the SEC a solicitation/recommendation statement on
Schedule 14D-9 (the “”), in each case, with respect to the tender offer. The
Company also intends to file with the SEC a proxy statement on Schedule 14A in connection with an extraordinary
general meeting of the Company’s shareholders, at which the Company’s shareholders will vote on certain proposed
resolutions (the “”) in connection with the transactions referenced herein, and will mail the
definitive proxy statement and a proxy card to each shareholder of the Company entitled to vote at the extraordinary general
meeting. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLIC